The role of glial cells in Parkinson's disease

Current Opinion in Neurology

Volumn 14, Issue 4, 2001, Pages 483-489

  Vila, Miquel ^a   Jackson Lewis, Vernice ^a   Guégan, Christelle ^a   Chu Wu, Du ^a   Teismann, Peter ^a   Choi, Dong Kug ^a   Tieu, Kim ^a   Przedborski, Serge ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUTAMIC ACID; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE;

ASTROCYTE; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; GLIA CELL; MICROGLIA; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SUBSTANTIA NIGRA;

ASTROCYTES; CHEMOKINES; CYTOKINES; DOPAMINE; HUMANS; MICROGLIA; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0034904508     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200108000-00009     Document Type: Review

References (58)

1. Parkinsonism
2. Biochemical pathophysiology of Parkinson's disease
3. Adverse effects of levodopa in Parkinson's disease
4. Astrocytes and Parkinson's disease
5. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
6. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
7. Alterations in striatal glial fibrillary acidic protein expression in response to 6-hydroxydopamine-induced denervation
8. Glia: A curtain raiser
9. Microglia: Intrinsic immuneffector cell of the brain
10. Molecular profile of reactive astrocytes: Implications for their role in neurologic disease
11. Cytotoxicity of microglia
12. Glutathione peroxidase, glial cells and Parkinson's disease
13. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
14. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia
15. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease
16. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease
17. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains
18. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine exposure
19. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model
20. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
21. The parkinsonian toxin MPTP: Action and mechanism
22. Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine
23. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo
24. Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death
25. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture
26. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor
27. Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum
28. Functional recovery in parkinsonian monkeys treated with GDNF
29. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
30. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine model of Parkinson's disease
31. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease
32. RCS and Parkinson's disease: A view to a kill
33. Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease
34. Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson's disease
35. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide
36. Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced dopaminergic neurotoxicity
37. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)
38. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine and O,O′-dityrosine in brain tissue of MPTP-treated mice, a model of oxidative stress in Parkinson's disease
39. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions
40. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease
41. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease
42. Regulation of biosynthesis of nitric oxide
43. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages
44. Mediation of inflammation by cyclooxygenase-2
45. Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology
46. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex
47. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2
48. Prostaglandin H synthetase-mediated metabolism of dopamine: Implication for Parkinson's disease
49. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease
50. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain
51. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease
52. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients
53. IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease
54. FceRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells
55. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease
56. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine mouse model of Parkinson's disease
57. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease
58. Reply: A new look at the pathogenesis of Parkinson's disease